Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Lijing Jiao1,2†, Jianfang Xu3†, Jianli Sun4, Zhiwei Chen5, Yabin Gong2, Ling Bi2, Yan Lu2, Jialin Yao2, Weirong Zhu6, Aihua Hou7, Gaohua Feng8, Yingjie Jia9, Weisheng Shen10, Yongjian Li11, Ziwen Zhang12, Peiqi Chen2 and Ling Xu2,13*

1 Institute of Clinical Immunology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China, 2 Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China, 3 Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China, 4 Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, 5 Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China, 6 Department of Oncology, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China, 7 Department of Oncology, Yantai Hospital of Traditional Chinese Medicine, Yantai, China, 8 Department of Oncology, West China Hospital of Sichuan University, Sichuan, China, 9 Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, 10 Department of Oncology, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China, 11 Department of Oncology, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, China, 12 Department of Oncology, Changshu No.2 People’s Hospital, Changshu, China, 13 Tumor Institute of Traditional Chinese Medicine, Chinese Medicine Research Institute, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Background: To determine the clinical activity and safety of Chinese herbal medicine (CHM) combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) in patients with advanced pulmonary adenocarcinoma (ADC) and the ability of CHM combined with EGFR-TKI to activate EGFR mutations.

Methods: Three hundred and fifty-four patients were randomly assigned to EGFR-TKI (erlotinib 150 mg/d, gefitinib 250 mg/d, or icotinib 125 mg tid/d) plus CHM (TKI+CHM, N = 185) or EGFR-TKI plus placebo (TKI+placebo, N = 169). Progression-free survival (PFS) was the primary end point; the secondary end points were overall survival (OS), objective response rate (ORR), disease control rate (DCR), quality of life [Functional Assessment of Cancer Therapy-Lung (FACT-L) and Lung Cancer Symptom Scale (LCSS)], and safety.

Results: The median PFS was significantly longer for the TKI+CHM group (15.97 vs. 11.43 months, P = 0.0530). Patients with exon 19 deletion had a significantly longer PFS than with 21 L858R. The addition of CHM
INTRODUCTION

For advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) activating mutations (mainly exon 19 Del and exon 21L858R), EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been shown to result in superior outcomes when compared with platinum-based chemotherapy (Mok et al., 2009; Mitsudomi et al., 2010; Zhou et al., 2011; Rosell et al., 2012; Shi et al., 2017). Despite initial positive responses to EGFR-TKIs, most patients will have acquired resistance to the EGFR-TKIs, and the disease will progress within 9–14 months (Mok et al., 2009; Rosell et al., 2009; Mitsudomi et al., 2010; Zhou et al., 2011; Rosell et al., 2012; Shi et al., 2017). Although osimertinib has been shown to be effective for acquired resistance because of exon20 T790M, resistance to osimertinib tends to develop within a year (Mok et al., 2017) and is hard to address (Thress et al., 2015). Thus, optimizing the effect of EGFR-TKI is essential for the long-term survival of NSCLC patients. Efforts have been made to delay the acquired resistance to EGFR-TKI, such as adding chemotherapy to EGFR-TKI treatments (Cheng et al., 2016) or using osimertinib as the initial treatment for advanced NSCLC with sensitizing EGFR mutations (Ramalingam et al., 2018). However, these “overdraft” strategies might not benefit the patient’s overall survival (OS) and may be related with increased toxicity (Lee et al., 2017).

The yin-yang theory provides a macroscopic view of biological phenomena. Various cancer-associated genes and proteins have been reported to regulate various types of cancers in a yin-yang manner (Wei, 2018). Traditional Chinese medicine (TCM) views diseases as an imbalance between yin and yang, and the Chinese theory of yin-yang has been used in treatments, specifically making Chinese herbal medicine (CHM) an alternative therapy for NSCLC (Li et al., 2013; Han et al., 2016; Jiao et al., 2017).

The efficacy of CHM in combination with EGFR-TKI in delaying acquired resistance and prolonging PFS and OS has been demonstrated in several clinical trials (Yang et al., 2014; Hung et al., 2017; Yang et al., 2017). However, these trials have either been retrospective or have had small samples, and the influence of CHM on the T790M mutation has never been studied.

The current CATLA study was to determine whether the addition of CHM to EGFR-TKI (TKI+CHM) prolongs PFS compared with EGFR+placebo (TKI) in advanced pulmonary adenocarcinoma (ADC) patients who have an activating EGFR mutation.

PATIENTS AND METHODS

Patients

In the current study, the inclusion criteria are as follows: 1) pathologically or cytologically confirmed with stage IIIa–IV with ADC; 2) patients with the mutated EGFR will be subjected to the first-line target therapy; patients who have received at least one cycle platinum-containing chemotherapy regimens with disease progression/recurrence or intolerant/refuse and who have proceeded to chemotherapy will explore the second-line target therapy; 3) Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores of 0, 1, or 2; 4) age ≥ 18 years; 5) estimated life expectancy of at least 12 weeks; 6) no major organ dysfunction.

Patients were excluded if they had already received the targeted treatment (e.g., EGFR-TKI) or other anticancer treatments, such as immunotherapy or biologic therapy. Indeed, patients with symptomatic brain metastases should receive radiotherapy before enrollment, so palliative irradiation of bone lesions was allowed.

Study Design and Treatment

This multicenter, randomized, double-blind, placebo-controlled study compared first-generation EGFR-TKIs (gefitinib, erlotinib, or icotinib)+CHM versus EGFR-TKIs+placebo as the first- or second-line therapy in Chinese patients with advanced ADC and who had EGFR activating mutations. There were 15 sites in China at which the patients were recruited. All of the patients were given informed consent prior to conducting the study. The study procedures and informed consent form were approved by the Institutional Review Board of Longhua Hospital in Shanghai [Institutional Review Board (IRB) no. 2012LCSY018], and until May 28, 2018, the study will still be reviewed by IRB.

Random Assignment

Patients were randomly assigned to receive either EGFR-TKI+CHM (TKI+CHM) or EGFR-TKI (TKI) at a ratio of 1:1. The minimization method was implemented via central randomization on the Internet by a clinical research organization (CRO) (Shanghai Clinical Research Center, Shanghai, China); the patients were stratified by sex (male vs. female), age (<65 vs. ≥65), ECOG PS (0 vs. 1 vs. 2), staging (IIIA vs. IIIB vs. IV), smoking status (yes vs. no), first or second line, EGFR mutation status (19 Del vs. 21L858R vs. other rare mutations), TKI (gefitinib vs. erlotinib vs. icotinib), and by which center the patient was recruited from. During the study, clinicians and subjects were blinded to the type of treatment being given.
Treatment Protocol
Patients assigned to TKI+CHM received oral EGFR-TKI [erlotinib (Roche, Switzerland) 150 mg, gefitinib (AstraZeneca, UK) 250 mg, or icotinib (Beta, China) 125 mg per dose, three times per day; the drug was chosen by the patients] plus oral CHM.

TCM Syndrome Differentiation and CHM Preparation
CHM was chosen from three prescriptions based on TCM syndrome differentiation: a qi-benefiting recipe, a yin-nourishing recipe, and a qi-yin benefiting recipe. One experienced TCM physician was assigned to differentiation syndromes and collected the baseline information. TCM diagnostic data and the prescribed medication for 1 month were given at the first visit. The bioactive components were extracted from water. Some quality control markers were selected by referring to the Chinese Pharmacopoeia (2015 edition), and the quantitative analysis was performed by high-performance liquid chromatography coupled with ultraviolet detection (HPLC-UV). The results were as follows: calycosin-7-O-beta-D-glucoside 0.012%, icariin 0.075%, psorale isoporalen 0.067% in formula I, rosmarinic acid 0.036%, and apigenin 0.0069% in formula IV, which provided the quality control of the formula. The three formulas were applied according to the following regimens (Supplementary Figure 1, Table 1) (Wang et al., 2018):

1. Formula I (including tonifying qi and warming yang granules) (Supplementary 1).
2. Formula II (nourishing yin granules) (Supplementary 2).
3. Formula III (yin-nourishing and qi-tonifying granules).
4. Formula IV (detoxifying and resolving masses granules) (Supplementary 3).

| TCM syndrome differentiation | Main symptoms | Tongue diagnosis | CHM regimens |
|-----------------------------|---------------|-----------------|--------------|
| 1. Qi syndrome deficiency   | Cough, large amount of sputum, loss of appetite, fatigue and weakness, pale and bulgy tongue. Secondary symptoms: spontaneous sweat, unshaped stool, thin superficial, and smooth pulse. | | Formula I + formula IV |
| 2. Yin syndrome deficiency  | Cough, small amount of sputum, dried mouth, red tongue. Secondary symptoms: night sweats, insomnia, low fever, thready pulse, rapid pulse. | | Formula II + formula IV |
| 3. Qi and yin syndrome deficiency | Cough, small amount of sputum, fatigue and weakness, dried mouth without polydipsia. Secondary symptoms: spontaneous sweat, night sweats, reddish tongue or tongue with teeth imprints, thready and weak pulse. | | Formula III + formula IV |

*Based on the Chinese Medicine New Medicine Clinical Practice Guideline (trial implementation) (published by China Medical Science Press in 2002) and Shanghai Chinese Medicine Routine Practice (written by the Shanghai Municipal Commission of Health and Family Planning).
We used the same method to prepare CHM and the placebo granules as previously reported (Wang et al., 2018). CHM granules (batch numbers 1208304, 1208303, and 1207357) were manufactured by Tianjiang Pharmaceutical Co., Ltd. (Jiangyin, Jiangsu Province, China) according to the good manufacturing practice (GMP) requirements. Three kinds of oral placebos were matched by weight, color, smell, taste, and packaging according to the three CHM formulas. The placebo was produced with flavorings and food by the same manufacturer but without the medical ingredients. The patients took the Chinese medicine applications on the same day as EGFR-TKI. The CHM granules were dissolved into 150 ml of warm water to drink twice per day after a meal until the end of the EGFR-TKI treatment. Clinical research pharmacists took part in and supervised the procedures.

EGFR-TKI and CHM treatment lasted until disease progression, unacceptable toxicity, or any other study discontinuation criteria were met. According to previous studies on drug-related toxicities (Melosky and Hirsh, 2014; Califano et al., 2015), dose adjustments or delays were implemented. For EGFR-TKI-treated patients with serious diarrhea, rashes, or any other EGFR-TKI-related adverse event (AE), the dosage could be stopped for up to 14 days, and appropriate symptomatic treatment could be provided. EGFR-TKI was stopped once interstitial lung disease occurred. For CHM-treated patients with abnormal liver function, poor appetite, nausea, diarrhea, and other gastrointestinal AEs, CHM could be delayed up to 14 days.

Outcome Measures
The primary endpoint was PFS, which was measured with the date of the videography from a random assignment to the date of objective progression or death by the researcher. The secondary endpoints included a comparison of OS, ORR, DCR, quality of life (QoL), and safety.

Computed tomography or magnetic resonance imaging were used to assess tumor at baseline and every 8 weeks until disease progression. Patients who received more than 80% of the expected dose of EGFR-TKI and CHM were considered adherent. We recorded treatment-emergent AEs (TEAEs) per the Medical Dictionary for Regulatory Activities (version 15.0) and graded them using the National Cancer Institute’s common terminology criteria for adverse events (version 3.0).

QoL was collected using the Functional Assessment of Cancer Therapy–Lung (FACT-L) questionnaire (Cella et al., 2002; Thongprasert et al., 2011) and the Lung Cancer Symptom Scale (LCSS) (Hollen et al., 1999).

Statistical Analysis
All patients were randomly assigned to treatment groups and had received at least one dose of CHM to be counted in the efficacy analyses. The safety population consisted of all patients (418 cases), including 64 EGFR-wide-type patients who had received at least one dose of the study drug.

The primary PFS end point was used to estimate the sample size. Approximately 95 PFS events were expected if 274 patients were enrolled (1:1), here with an inspection level of α = 0.05 and power 1−β = 0.80, hazard ratio (HR) = 0.56 for TKI+CHM versus TKI alone, corresponding to a 7-month improvement in PFS based on previous trials using CHM or TKI alone in the first-line therapy. The PFS of the second-line EGFR-TKI targeted therapy was 7 months (Kim et al., 2008), with an inspection level of α = 0.05 and power 1−β = 0.80, HR = 0.50; here, CHM plus EGFR-TKI may increase PFS to 12 months in the second-line therapy of advanced lung adenocarcinoma with EGFR mutation. There were 129 cases after calculation (64 cases in each group). It took 18 months to recruit the patients, and the research lasted for 36 months. Because of a 10% expulsion rate, there were a total of 443 cases in the study.

PFS is illustrated by the Kaplan–Meier survival curve and log-rank test. For the PFS and tumor response, an adjusted Cox regression model was used to estimate the adjusted HRs for differences between the treatment arms with the selected prognostic factors, including the EGFR mutation type, age, sex, EGFR-TKI drugs, treatment line, smoking status, and ECOG PS. Fisher’s exact test was used to compare tumor response rates and the incidence of TEAEs between the arms. P < 0.05 was considered statistically significant. Analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). Shanghai Clinical Research Center (SCRC) experts were invited to manage the statistical analysis.

RESULTS

Patient Disposition
In the current study, 451 patients were enrolled and randomized, and 418 patients were included in full analysis set, including 64 patients with an unknown type of EGFR in the second-line therapy; these 64 patients were excluded from the final analysis (December 28, 2012 to August 22, 2016). For the present study, 354 patients with EGFR activating mutations received at least one dose of the treatments used for the study and were assigned to either TKI+CHM (N = 185) or TKI (N = 169; Figure 1). Demographic and baseline clinical characteristics were matched, save for the clinic stage between the arms (Table 2). In the TKI+CHM arm, the mean number for completed treatment was 12.62 (range, 0–52 months) and 10.75 (range, 0–38 months) in the TKI arm. The mean relative dose-intensity in the TKI+CHM arm, the mean number for completed treatment was 98.92% and 98.22% (EGFR-TKI and CHM, respectively), and 98.82% (placebo) in the TKI arm. There was no difference in the proportion of patients adhering to TKI in both arms, 99.45% (184 of 185 patients) in the TKI+CHM arm and 98.82% (167 of 169 patients) in the TKI arm.

Clinical Activity
At the end of the study period (January 2018), 207 patients (58.5%) had major disease-related events (objective disease progression or death). Statistically significant prolongation of PFS can be seen in the TKI+CHM arm (median, 13.5 months; 95% CI, 10.3–16.6 months) compared with the TKI monotherapy (median, 10.9 months; 95% CI, 9.0–12.5 months; HR, 0.68; 95% CI, 0.51–0.90; P = 0.0064; Table 3; Figure 2A). A statistically significant improvement in PFS in the TKI+CHM arm versus the TKI arm was observed in patients receiving TKI+CHM as the first-line treatment rather than second-line treatment (Table 3;
Figure 2B and C). PFS significantly improved for patients with exon 19 deletions in the TKI+CHM arm (Table 3; Figure 2D), and no obvious difference was observed for patients with exon 21 L858R point mutations between the groups (Table 3; Figure 2E). Analyses of PFS in other patient subgroups, such as females, ≥65 years, icotinib, and never-smokers were consistent with the intent-to-treat (ITT) results (Table 3).

The addition of CHM to TKI significantly improved the ORR (64.32% vs. 52.66%, P = 0.026). For patients taking EGFR-TKI as the first-line therapy, CHM significantly improved the ORR. When used as the second-line treatment, TKI+CHM significantly improved the ORR (66.67% vs. 46.67%, P = 0.0398). CHM improved the ORR mainly for patients with a 19 Del (69.47% vs. 51.52%, P = 0.0106) rather than 21L858R. The choice of CHM had no influence on ORR, but icotinib demonstrated a better ORR than the other two TKIs (69.39% vs. 55.32%, P = 0.0441) (Table 3).

**Exon20 T790M**

Forty-eight patients (27 cases in the TKI+CHM group and 21 cases in the TKI group) underwent amplification refractory mutation system (ARMS) detection for exon 20 T790M using ctDNA or formalin-fixed paraffin-embedded (FFPE) tissue analysis at the time of tumor progression; 33.33% (9/27) in the TKI+CHM arm and 42.86% (9/21) in the TKI arm were found with exon 20 T790M (P = 0.558).

**QoL**

There were 326 patients who took part in the questionnaire part of the present study: 92.43% (171/185) in the TKI+CHM arms and 91.72% (155/169) in the TKI arms. The changes in the QoL scores were analyzed for patients at baseline and at 7 months postbaseline QoL assessment (123 in the EGFR-TKI+CHM arm and 116 in the
There was no difference in baseline QoL scores in all domains and items between the two groups (P > 0.05) (Supplementary 4 and 5). The most common symptoms were fatigue for advanced-stage lung cancer patients (mean 37.7 ± 25.1), followed by appetite loss (mean 30.5 ± 24.3), dyspnea (mean 25.7 ± 24.8), and pain (mean 19.2 ± 23.4). The improvement ratios in the FACT-L were significantly higher in the treatment group than in the placebo arm (20.54% [38/185] vs. 15.98% [27/169], P = 0.0160) (Figure 3A). For the LCSS pulmonary symptoms score, the patients reported clinically meaningful improvement in their overall QoL, overall symptomatic distress, and normal activity. The improvement ratios in the treatment group were significantly higher than the placebo arm in overall QoL (P = 0.0109), overall symptomatic distress (P = 0.0026), and normal activity (P = 0.0048) (Figure 3B).

### Safety Outcomes
Mild drug-related TEAEs were reported and included diarrhea, pruritus, skin rash, loss of appetite, and fatigue in the TKI arm. There was no difference in baseline QoL scores in all domains and items between the two groups (P > 0.05) (Supplementary 4 and 5). The most common symptoms were fatigue for advanced-stage lung cancer patients (mean 37.7 ± 25.1), followed by appetite loss (mean 30.5 ± 24.3), dyspnea (mean 25.7 ± 24.8), and pain (mean 19.2 ± 23.4). The improvement ratios in the FACT-L were significantly higher in the treatment group than in the placebo arm (20.54% [38/185] vs. 15.98% [27/169], P = 0.0160) (Figure 3A). For the LCSS pulmonary symptoms score, the patients reported clinically meaningful improvement in their overall QoL, overall symptomatic distress, and normal activity. The improvement ratios in the treatment group were significantly higher than the placebo arm in overall QoL (P = 0.0109), overall symptomatic distress (P = 0.0026), and normal activity (P = 0.0048) (Figure 3B).

### Safety Outcomes
Mild drug-related TEAEs were reported and included diarrhea, pruritus, skin rash, loss of appetite, and fatigue in the TKI arm. There was no difference in baseline QoL scores in all domains and items between the two groups (P > 0.05) (Supplementary 4 and 5). The most common symptoms were fatigue for advanced-stage lung cancer patients (mean 37.7 ± 25.1), followed by appetite loss (mean 30.5 ± 24.3), dyspnea (mean 25.7 ± 24.8), and pain (mean 19.2 ± 23.4). The improvement ratios in the FACT-L were significantly higher in the treatment group than in the placebo arm (20.54% [38/185] vs. 15.98% [27/169], P = 0.0160) (Figure 3A). For the LCSS pulmonary symptoms score, the patients reported clinically meaningful improvement in their overall QoL, overall symptomatic distress, and normal activity. The improvement ratios in the treatment group were significantly higher than the placebo arm in overall QoL (P = 0.0109), overall symptomatic distress (P = 0.0026), and normal activity (P = 0.0048) (Figure 3B).
| Outcome | EGFR-TKI+CHM (N = 185) | EGFR-TKI+placebo (N = 169) | P | HR statistical values |
|---------|------------------------|-----------------------------|---|----------------------|
| PFS     | 13.50 (11.20, 16.46)    | 10.94 (8.97, 12.45)         | 0.0064 | 0.68 (0.51, 0.90) | 0.0057 |
|         | Adjusted               |                             |     |                      |        |
| Median PFS by first- or second-line treatment, months (95% CI) | | | | | |
| First line | 15.97 (12.09, 16.66)     | 10.97 (8.94, 13.37)         | 0.0447 | 0.78 (0.39, 1.55) | 0.4739 |
| Second line | 11.43 (9.88, 16.28)      | 9.23 (8.80, 13.83)          | 0.0530 | 1.41 (0.47, 4.21) | 0.5931 |
| Median PFS by sex, months (95% CI) | | | | | |
| Male | 12.71 (9.86, 29.70)      | 10.48 (8.771, 14.47)        | 0.0523 | 0.93 (0.51, 1.70) | 0.8137 |
| Female | 16.07 (11.14, 16.89)     | 11.24 (8.44, 13.60)         | 0.0488 | 1.76 (0.16, 19.57) | 0.6463 |
| Median PFS by age, months (95% CI) | | | | | |
| <65 years | 12.68 (10.68, 16.07)     | 10.48 (8.44, 13.37)         | 0.1158 | 0.76 (0.55, 1.06) | 0.1167 |
| ≥65 years | 18.83 (11.43,-)          | 11.56 (8.94, 14.29)         | 0.0298 | 0.59 (0.35, 0.98) | 0.0436 |
| Median PFS by EGFR-TKI drugs, months (95% CI) | | | | | |
| Gefitinib | 16.07 (9.92, 16.66)      | 10.19 (8.41, 14.29)         | 0.2284 | 0.78 (0.39, 1.55) | 0.4739 |
| Erlotinib | 11.91 (1.94, 31.28)      | 6.82 (0.72,-)               | 0.0973 | –                     | –       |
| Icotinib | 13.21 (10.37, 18.56)     | 11.17 (8.90, 13.47)         | 0.0212 | 1.27 (0.29, 2.10) | 0.5507 |
| Median PFS by EGFR mutation type, months (95% CI) | | | | | |
| Exon 19 deletion | 15.97 (11.79, 16.89)    | 10.87 (8.90, 13.37)         | 0.0099 | 0.67 (0.29, 1.57) | 0.3593 |
| Exon 21 L858R point mutation | 12.68 (9.86, 17.41)    | 11.24 (10.18, 19.81)        | 0.7819 | 1.72 (0.40, 7.33) | 0.4629 |
| Other mutation | 10.96 (5.52, 16.39)     | 12.12 (6.01, −)             | 0.5860 | –                     | –       |
| Median PFS by TCM syndrome, months (95% CI) | | | | | |
| Qi deficiency | 12.71 (8.57, 16.43)    | 10.05 (8.08, 11.70)         | 0.057 | 0.96 (0.40, 2.31) | 0.9340 |
| Yin deficiency | 13.20 (7.49, 16.46)    | 12.45 (10.18, 19.81)        | 0.7819 | 1.72 (0.40, 7.33) | 0.4629 |
| Qi and yin deficiency | 16.26 (11.20, 18.53)  | 10.87 (8.64, 13.60)         | 0.0281 | 0.89 (0.32, 2.46) | 0.8180 |
| Median PFS by ECOG PS score, months (95% CI) | | | | | |
| 0 | 16.46 (5.22,-)           | 12.12 (5.52,−)              | 0.6148 | –                     | –       |
| 1–2 | 13.50 (11.20, 16.43)     | 10.94 (8.97, 12.45)         | 0.0081 | 0.92 (0.51, 1.66) | 0.7723 |
| Median PFS by smoking status, months (95% CI) | | | | | |
| Never-smokers | 16.07 (11.43, 16.89)  | 10.97 (8.57, 2.45)          | 0.0045 | 0.64 (0.47, 0.88) | 0.0053 |
| Present smokers and light former smokers | 11.20 (9.17, 5.97)      | 10.94 (8.97, 6.49)          | 0.9927 | 0.96 (0.54, 1.72) | 0.9029 |
| Median PFS by stage, months (95% CI) | | | | | |
| III | 11.30 (8.18,-)           | 10.48 (1.08,-)              | 0.2959 | 1.14 (0.10, 13.27) | 0.9183 |
| IV | 13.50 (11.20, 6.46)      | 10.97 (8.97, 12.94)         | 0.0087 | 0.99 (0.54, 1.81) | 0.9845 |
| Median TtPD, months (95% CI) | | | | | |
| 16.0 (13.57, 18.43) | 10.96 (9.45, 12.48) | 0.0020 | 0.64 (0.48, 0.85) | 0.0020 |
| OS* | 42 (22.70) | 32 (18.93) | – | – | – |
| Tumor response, No. (%) | | | | | |
| CR | 0 (0.00) | 0 (0.00) | – | – | – |
| PR | 119 (64.32) | 89 (52.66) | – | – | – |
| SD | 57 (30.81) | 74 (43.78) | – | – | – |
| PD | 9 (4.86) | 6 (3.56) | – | – | – |
| ORR(CR+PR) | 119 (64.32) | 89 (52.66) | 0.0260 | – | – |
| DCR(CR+PR+SD) | 176 (96.76) | 163 (96.45) | 1.0000 | – | – |
| Median DoR, months (95% CI) | | | | | |
| 9.53 (8.79, 10.23) | 8.00 (6.70, 10.29) | 0.5000 | – | – |
| Tumor response by first or second line | | | | | |
| First line | 79 (63.20) | 68 (54.84) | 0.1798 | – | – |
| Second line | 40 (66.67) | 21 (46.67) | 0.0398 | – | – |
| Tumor response by EGFR-TKI drugs | | | | | |
| Gefitinib | 69 (60.49) | 37 (53.62) | 0.3965 | – | – |
| Erlotinib | 2 (33.33) | 0 (0.00) | 0.1213 | – | – |
| Icotinib | 68 (69.39) | 52 (55.32) | 0.0441 | – | – |
| Tumor response by EGFR mutation | | | | | |
| Exon 19 deletion | 66 (69.47) | 51 (51.52) | 0.0106 | – | – |
| Exon 21 L858R point mutation | 51 (57.95) | 36 (53.73) | 0.5997 | – | – |
| Other mutation | – | – | – | – | – |
TABLE 3 | Continued

| Outcome                                      | EGFR-TKI+CHM (N = 185) | EGFR-TKI+placebo (N = 169) | P a | HR statistical values b |
|----------------------------------------------|------------------------|---------------------------|-----|-------------------------|
|                                              |                        |                           |     | HR (95% CI)             | P   |
| Tumor response by TCM syndrome              |                        |                           |     |                         |     |
| Qi deficiency                                | 38 (57.58)             | 32 (45.71)                | 0.1666 | –                      | –   |
| Yin deficiency                               | 21 (72.41)             | 17 (65.38)                | 0.5773 | –                      | –   |
| Qi and yin deficiency                        | 60 (66.67)             | 40 (54.79)                | 0.1217 | –                      | –   |

EGFR, epidermal growth factor receptor; HR, hazard ratio; ITT, intent to treat; ORR, overall response rate; OS, over survival; PFS, progression-free survival; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; DoR, duration of response.

* A two-sided P-value was derived from log-rank test for PFS and from Fisher’s exact test for tumor response.

* All HRs and corresponding P-values were unadjusted, except as otherwise noted. HR values for TKI+CHM and TKI were derived from a Cox regression analysis, and one- and two-sided P-values were derived from the Wald test from the Cox model.

* Adjusted for EGFR mutation type, age, sex, smoking status, ECOG performance status, stage, TKI drugs, TCM syndrome, and prior chemotherapy therapy.

* Defined as the time from random assignment to the first date of disease progression.

* Defined as the time from random assignment to the date of death from any cause.

* Percentages may not add up to 100% because of rounding.

* Adjusted as the time from the date of the first CR or PR to the first date of progressive disease (per RECIST version 1.1).

* Analyzed in the ITT population with CR or PR.

FIGURE 2 | PFS in the (A) intent-to-treat population, (B) first-line EGFR-TKI subgroup, (C) second-line EGFR-TKI subgroup, (D) exon 19 deletion subgroup, (E) L858R point mutation subgroup; PFS, progression-free survival; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitors.
FIGURE 3 | The proportion of patients with different QoL changes during the treatment according to the results of FACT-L, TOI, LCS and the LCSS. The assessments (and improvement rate) were calculated for the FACT-L, TOI, and LCS scores ("improved," "stabled," and "worsened"). A clinically relevant improvement was defined as a change from a baseline of six points for FACT-L and TOI and two points for LCS, here maintained for 21 or more days. To demonstrate trends, the baseline score for each item of the LCSS and for the average score was subtracted from the 7-month scores and then categorized as worse (>10 mm), stable (−10 to 10 mm), or improved (<−10 mm). QoL, quality of life; FACT-L, Functional Assessment of Cancer Therapy–Lung; TOI, trial outcome index (the sum of physical, functional well-being, and LCS domains); LCS, lung cancer subscale; LCSS, Lung Cancer Symptom Scale.

TABLE 4 | Most common adverse events of all grades reported by intervention at 7 months of treatment.

| Adverse event          | EGFR-TKI+CHM (N = 115) | EGFR-TKI+placebo (N = 99) | P-value |
|------------------------|-------------------------|---------------------------|---------|
|                        | Grade 0 | Grade 1 | Grade 2 | Grade 3 or 4 | Grade 0 | Grade 1 | Grade 2 | Grade 3 or 4 |         |
| Fatigue                | 94 (81.74%) | 20 (17.39%) | 1 (0.87%) | 0 | 64 (64.65%) | 35 (35.35%) | 0 (0.00%) | 0 | 0.0091 |
| Loss of appetite       | 110 (95.65%) | 4 (3.48%) | 1 (0.87%) | 0 | 86 (86.87%) | 12 (12.12%) | 1 (1.01%) | 0 | 0.0435 |
| Diarrhea               | 110 (95.65%) | 5 (4.35%) | 0 (0.00%) | 0 | 86 (86.87%) | 13 (13.13%) | 0 (0.00%) | 0 | 0.0213 |
| Pruritus               | 97 (84.35%) | 17 (14.78%) | 1 (0.87%) | 0 | 59 (59.60%) | 39 (39.39%) | 1 (1.01%) | 0 | 0.0001 |
| Skin rash              | 93 (80.87%) | 19 (16.52%) | 3 (2.61%) | 0 | 57 (57.58%) | 40 (40.40%) | 2 (2.02%) | 0 | 0.0013 |
proportion of patients with study drug-related TEAEs resulting in treatment withdrawal was higher in the TKI arm than in the TKI+CHM arm (P = 0.6670) (Table 5). Here, 83.33% of the patients (10 of 12 patients) undergoing the EGFR-TKI treatment suffered from a treatment interruption as a result of an AE in the TKI+CHM arm and 72.73% (8 of 11 patients) in the TKI-alone arm (P = 0.6400). Also, 8.33% of the patients decreased their dose of EGFR-TKI as a result of an AE in the TKI+CHM arm (1 of 12 patients). In the TKI arm, one patient switched to gefitinib instead of icotinib because of the anaphylactic reaction caused by icotinib.

**DISCUSSION**

To the best of our knowledge, the CATLA is the first prospective head-to-head phase 3 study to examine the efficacy and safety of first- and second-line TKI+CHM versus EGFR-TKI in patients with advanced adenocarcinoma whose tumors harbor EGFR activating mutations. EGFR-TKIs have proved effective in first- or second-line therapy for advanced NSCLC (Mok et al., 2009; Zhou et al., 2011; Shi et al., 2017). A meta-analysis of randomized trials of treatment-native patients reported that EGFR-TKIs statistically significantly prolonged PFS overall, but because of the high rate of crossover at progression, EGFR-TKI had a shorter OS than those who were randomly assigned to chemotherapy (12.8 months, 95% CI: 11.4–14.3 vs. 19.8 months, 95% CI: 17.6–21.7) (Lee et al., 2017).

EGFR T790M is a mutation associated with acquired resistance to EGFR-TKI therapy and has been reported in approximately 60% of patients with disease progression after the initial treatment with erlotinib and gefitinib (Yu et al., 2013; Yu et al., 2015). Efforts have been made to delay resistance to EGFR-TKI. Pemetrexed plus gefitinib results in a prolonged PFS (median, 15.8 months; 95% CI, 12.6–18.3 months) when compared with gefitinib alone (median, 10.9 months; 95% CI, 9.7–13.8 months; [HR], 0.68; 95% CI, 0.48–0.96; P = 0.014) (Ramalingam et al., 2018). Osimertinib has shown to the potential to prolong PFS to 22.1 months in treatment-naive patients with EGFR advanced NSCLC (Yang et al., 2014). However, these strategies overdraft subsequent chemotherapy and targeted therapy and might not benefit OS.

CHM treatment could be given according to the patients’ physical status, syndrome differentiation, and type of cancer treatment. Patients with lung cancer are receiving the theoretical directions of “treatment of cancer by strengthening antipathogenic ability.” In China, CHM as an adjuvant therapy has shown the potential to reduce chemotherapy toxicity, prolong survival rate, enhance immediate tumor response, and improve Karnofsky performance status (KPS) in advanced NSCLC patients, but its efficacy remains largely unexplored (Li et al., 2013). CHM combined with EGFR-TKI has been demonstrated to be effective in both retrospective and small sample prospective clinical trials (Yang et al., 2014; Hung et al., 2017). The results of the CATLA study conclusively show that TKI+CHM as a first- or second-line therapy provides significantly prolonged PFS and ORR compared with TKI alone in ADC with EGFR activating mutations, here prolonging the median PFS by 5.0 months in the first-line population.

For NSCLC patients with sensitive EGFR mutations, the application of EGFR-TKIs as a first- or second-line therapy did not result in a difference in OS (Mok et al., 2009; Rosell et al., 2012). When used as the first- or second-line therapy, EGFR-TKI resulted in a PFS of 11.0 and 9.2 months and an ORR of 54.8% and 46.7%, which is in accordance with the well-defined efficacy of TKIs (Mok et al., 2009; Mitsudomi et al., 2010; Zhou et al., 2011; Rosell et al., 2012; Shi et al., 2017). To date, no head-to-head trials have been conducted on the difference of efficacy between these EGFR-TKIs (erlotinib, gefitinib, or icotinib) as a first-line therapy in mutated NSCLC populations. By looking at the indirect and integrated comparisons using data from existing clinical trials, there seems to be no difference in efficacy between these TKIs. Twelve phase III RCTs involving 1,821 participants with an EGFR mutation were included in a network meta-analysis, which indicated that erlotinib, gefitinib, and icotinib shared an equivalent efficacy (Liang et al., 2014). In addition, a head-to-head trial between icotinib and gefitinib as a second-line therapy for 68 NSCLC patients with EGFR activating mutations reported that icotinib (n = 29) was not inferior to gefitinib (n = 39) in terms of PFS (HR 0.78, 95% CI 0.42–1.28; 7.8 months [95% CI 3.7–12.2] and 5.3 months [95% CI 3.7–9.3]; P = 0.32, respectively) (Shi et al., 2013). The three kinds of first-generation EGFR-TKIs available in China at the time the study was designed demonstrated comparable efficacy. In the CATLA study, because of the limitations of research funding, the gefitinib, erlotinib, and icotinib treatments applied were paid for by the patients. EGFR-TKI was chosen by the patients; 54.24% (192/354) received icotinib, 42.37% (150/354)

---

**TABLE 5 | Summary of adverse event rates n (%).**

|                      | EGFR-TKI+CHM (N = 213) | EGFR-TKI+placebo (N = 205) | P-value |
|----------------------|------------------------|---------------------------|---------|
| At least one AE* (include SAE**) |                        |                           |         |
| Yes                  | 12 (6.49§)             | 11 (5.4)                  |         |
| No                   | 201 (94.40)            | 194 (94.60)               | 1.0000  |
| At least one AE related to the medication (including SAE) |                        |                           |         |
| Yes                  | 9 (75.00)              | 6 (54.50)                 | 0.4000  |
| No                   | 3 (25.00)              | 5 (45.50)                 |         |
| At least one SAE     |                        |                           |         |
| Yes                  | 1 (8.30)               | 2 (18.20)                 | 0.5900  |
| No                   | 11 (91.70)             | 9 (81.80)                 |         |
| At least one SAE related to medication |                        |                           |         |
| Yes                  | 1 (8.33)               | 2 (18.20)                 | 0.5900  |
| No                   | 11 (91.67)             | 9 (81.80)                 |         |
| Drop out or stop trial because of AE and SAE |                        |                           |         |
| Yes                  | 3 (25.00)              | 4 (38.40)                 | 0.6670  |
| No                   | 9 (75.00)              | 7 (63.60)                 |         |
| Death because of AE and SAE |                        |                           |         |
| Yes                  | 0 (0.00)               | 1 (9.10)                  | 0.4780  |
| No                   | 12 (100.00)            | 10 (90.90)                |         |

*AE, adverse event. **SAE, severe adverse event. §AE: Fever (n = 1), gastrointestinal tract reactions (n = 2), pneumonia (n = 3), increased alanine aminotransferase (ALT) concentration (n = 4), and dizziness (n = 2); wAE: Gastrointestinal tract reactions (n = 3), herpes zoster (n = 1), pleural effusion (n = 1), heart disease (n = 1), increased ALT concentration (n = 4), anaphylactic reaction (n = 2), and thrombus (n = 1).
chance of gefitinib, and only 3.39% (12/354) took erlotinib. Although we did not allocate the type of TKI, we used it as one of the random factors to ensure the groups were balanced. The proportion of patients receiving gefitinib, erlotinib, and icotinib was 40.83%, 3.55%, and 55.62%, respectively, in EGFR-TKI+placebo group and 43.78%, 3.24%, and 52.97%, respectively, in the EGFR+CHM group. There was no statistical difference in TKI selection between the two groups (P > 0.05) (Table 2). The results show that gefitinib and icotinib have a similar efficacy.

Activating EGFR mutation types included in the current CATLA study trial were exon19 Del (194/354; 54.80%) and exon21 L858R (155/354; 43.79%). Three patients with exon 18 G719X, one with concurrent exon 18 G719X and exon19 Del, and one with concurrent exon19 Del and exon 20 ins were enrolled and included in the ITT group. A significant difference for PFS was observed between the treatments in EGFR-mutated subgroups (exon 19 Del/21 L858R) and TKI+CHM for patients with 19 Del prolonged PFS (median, 15.97 months; 95% CI, 11.79–16.89 months) compared with TKI alone (median, 10.87 months; 95% CI, 8.90–13.47 months; adjusted HR, 0.67; 95% CI, 0.29–1.57; P = 0.0099). However, there is no obvious benefit regarding treatment type for 21 L858R (12.68 vs. 11.24 months, P = 0.1129). In a subgroup analysis, CHM combined with gefitinib seems to prolong the PFS without significance (12.63 months vs. 9.67 months, P = 0.156), while CHM+icotinib seems to bring no benefits (11.13 months vs. 11.87 months, P = 0.550, in Supplementary Tables 6 and 7). Our study aims to evaluate the clinical efficacy of CHM when combined with TKI, and the mechanism of action of CHM needs further study. Not only did CHM improve the ORR by 20% with TKI in the second-line treatment, but it also improved the ORR by 18%, mainly for patients with 19 Del rather than 21L858R mutation. In general, increasing numbers of studies have shown that patients with different driving mutations have different response to EGFR-TKIs, and the prognosis of exon Del19 is better than that of exon 21L858R, which is consistent with the results of our study (Ke et al., 2017). First, the difference in prognosis between 19 Del and 21 L858R might be related, not only to the efficacy of CHM, but also EGFR-TKIs itself. EGFR has been proved to be more effective for PFS and OS in patients with 19 Del than in those with exon 21L858R mutation (HR, 0.75; 95% CI 0.65 to 0.85; P < 0.001) (Zhang et al., 2014). TKI therapy might change the natural history of patients harboring an EGFR mutation, converting Del19 lung cancer from a disease with a poor prognosis to one with a more favorable prognosis (Riely et al., 2006). Second, the difference in intrinsic structural basis between these two kinds of lung cancer explains the possible mechanisms and different drug sensitivity affecting ATP’s binding ability. Del19 removes three to eight residues from the loop leading into the αC-helix, whereas the L858R mutation lies in the activation loop of the kinase (Furuyama et al., 2013). Third, the resistance mechanisms (including T790M mutation, mesenchymal-epithelial transition amplification, histological transformation, PIK3CA mutation, and anaplasticlymphoma kinase fusion) differ between Del19 and L858R mutation patients (Ke et al., 2017). The predilection for the T790M mutation in the Del19 population (50.4% vs. 36.5%) might help explain why these patients tend to survive longer than patients with the L858R mutation.

The choice of CHM has no influence on the ORR, but icotinib has demonstrated a better ORR than the other two. The ORRs were similar and in accordance with earlier studies. In the current study, it seems that CHM did not change the current situation of the poorer prognosis for patients with exon L858R. Maybe CHM has a greater influence on different drug resistance pathways. However, due to the limitation of this study, the mechanism of CHM delaying TKI resistance need further exploration.

Meanwhile, several studies have shown that CHM could play an important role in EGFR-TKI resistance (Li et al., 2016; Xu et al., 2018). EGFR T790M is a mutation associated with acquired resistance to EGFR-TKI therapy and has been reported in approximately 60% of patients with disease progression after initially being given erlotinib and gefitinib (Yu et al., 2013; Yu et al., 2015). Patients progressed after first-generation EGFR-TKIs were given because of the T790M mutation has a superior efficacy when being treated with osimertinib versus chemotherapy (71% ORR and 10.1 months PFS) (Mok et al., 2017). Thus, a treatment prolonging the PFS of TKI by blocking T790M might not benefit overall OS. We analyzed the EGFR mutation status using ctDNA or tissue at the time of tumor progression to explore the mechanism of CHM in delaying the acquired resistance of TKI. Our results show that CHM delays, rather than blocks, the occurrence of T790M, and patients might still benefit from subsequent osimertinib treatment.

The current study’s drug-related AEs were less frequent in the TKI+CHM arm than in the TKI arm. The most common drug-related TEAEs were diarrhea, pruritus, skin rash, loss of appetite, and fatigue. TCM views health as a balance between yin and yang, and CHM are prescribed accordingly to rebuild that balance. Hence, CHM could help decrease the common adverse reactions because rashes, diarrhea, and so forth may affect patients’ QoL.

Through the current prospective, multicenter, randomized, placebo-controlled randomized clinical study, we confirmed the role of CHM in combination with EGFR-TKI. CHM was also recommended because of its low cost. However, we still need to collect the OS data, which will help determine if CHM can benefit OS.

However, the current study included 91.53% (324/354) stage IV patients; the impact of the imbalance of the clinical staging is relatively small (Table 1). Furthermore, there was no difference in the median PFS between stage III and IV (P > 0.05) (Table 3). When we used the stage as a covariate in the multivariate regression analysis, it proved that the stage did not affect the prognosis (Table 3) (P > 0.05). In addition, we analyzed the baseline status of brain, bone, and liver metastasis of stage IV patients. The distribution of distant metastasis that could affect PFS and OS was balanced between the two groups.

The current CATLA study provides the first conclusive evidence that the combination of EGFR-TKI and CHM provides a superior ORR and PFS versus EGFR-TKI alone as a first- and second-line treatment in patients whose tumors harbor EGFR activating mutations. However, the current study is limited to relatively small samples and uncontrolled EGFR-TKI types. In addition, clinical staging at the baseline was not well matched.
TCM has a long history of clinical observation and application because of its unique theoretical systems. Thus, the active ingredients of the CHM formula and its mechanism in delaying the acquired resistance of EGFR-TKIs remain unknown and need to be explored further.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of NCCN Clinical Practice Guidelines Oncology, Institutional Review Board of LongHua Hospital with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Institutional Review Board of LongHua Hospital in Shanghai (IRB no. 2012LCSY018).

AUTHOR CONTRIBUTIONS

Conception and design: LJ, JS, ZC, YG, JX, and LX. Financial support: LX; Administrative support: LX; Provision of study materials or patients: LJ, JS, ZC, YG, LB, JY, WZ, AH, GF, YJ, WS, YL, ZZ, PC, JX, and LX; Collection and assembly of data: LJ, JS, ZC, YG, LB, JY, WZ, AH, GF, YJ, WS, YL, ZZ, PC, JX, and LX; Data analysis and interpretation: LJ, YL, PC, JX, and LX; Manuscript writing: All authors; Final approval of manuscript: All authors; Accountable for all aspects of the work: All authors.

REFERENCES

Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., et al. (2015). Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs 75 (12), 1335–1348. doi:10.1007/s40265-015-0434-6

Cella, D., Eton, D. T., Fairclough, D. L., Bonomi, P., Heyes, A. E., Silberman, C., et al. (2002). What is a clinically meaningful change on the functional assessment of cancer therapy-lung (fact-l) questionnaire? Results from eastern cooperative oncology group (ecog) study 5592. J. Clin. Epidemiol. 55 (3), 285–295. doi:10.1016/S0895-4356(01)00477-2

Cheng, Y., Murakami, H., Yang, P. C., He, I., Nakagawa, K., Kang, J. H., et al. (2016). Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J. Clin. Oncol. 34 (27), 3258–3268. doi:10.1200/JCO.2016.66.9218

Furuyama, K., Harada, T., Iwama, E., Shiraishi, Y., Okamura, K., Ijichi, K., et al. (2013). Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer Sci. 104 (5), 584–589. doi:10.1111/cas.12125

Han, Y., Wang, H., Xu, W., Cao, B., Han, L., Jia, L., et al. (2016). Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients. Complement. Ther. Med. 24, 81–89. doi:10.1016/j.ctim.2015.12.008

Hollen, P. J., Graff, R. J., Kris, M. G., Eberly, S. W., and Cox, C. (1999). Normative data and trends in quality of life from the lung cancer symptom scale (LCSS). Support Care Cancer 7 (5), 140–148. doi:10.1007/s005200050344

Hung, H. Y., Tseng, Y. H., Liao, C. M., Chen, S. Y., Wu, T. P., Lee, Y. C., et al. (2017). The efficacy of traditional chinese herbal medicine in the treatment of EGFR mutated stage iv pulmonary adenocarcinoma patients who received first-line EGFR-TKI treatment. Integr. Cancer Ther. 16 (1), 126–131. doi:10.1177/1534735416645181

Jiao, L., Dong, C., Liu, J., Chen, Z., Zhang, L., Xu, J., et al. (2017). Effects of chinese medicine as adjunct medication for adjuvant chemotherapy treatments of non-small cell lung cancer patients. Sci. Rep. 7, 46524. doi:10.1038/srep46524

Ke, E. E., Zhou, Q., Zhang, Q. Y., Su, J., Chen, Z. H., Zhang, X. C., et al. (2017). A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with exon 19 deletions compared with those with L858R. J. Thorac. Oncol. 12 (9), 1368–1375. doi:10.1016/j.jtho.2017.05.018

Kim, E. S., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Wu, Y. L., et al. (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372 (9652), 1809–1818. doi:10.1016/S0140-6736(08)61758-4

Lee, C. K., Davies, L., Wu, Y. L., Mitsudomi, T., Inoue, A., Rosell, R., et al. (2017). Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival. J. Natl. Cancer Inst. 109 (6). doi:10.1093/jnci/djw279

Li, L., Wang, S., Zheng, F., Wu, W., and Hann, S. S. (2016). Chinese herbal medicine Fuzheng Kang-Ai decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt-mediated suppressing MUC1 expression. J. Ethnopharmacol. 194, 918–929. doi:10.1016/j.jep.2016.10.077

Li, S. G., Chen, H. Y., Ou-Yang, C. S., Wang, X. X., Yang, Z. J., Tong, Y., et al. (2013). Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer Sci. 104 (5), 584–589. doi:10.1111/cas.12125

Liang, W., Wu, X., Fang, W., Zhao, Y., Yang, Y., Hu, Z., et al. (2014). Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced NSCLC. Int. J. Clin. Oncol. 19 (1), 57–66. doi:10.1007/s10147-013-0780-8

Zhang, Y., Wu, T., Fang, W., Zhang, Y., Yang, Z., Lu, Z., et al. (2017). The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 12 (8), e0180495. doi:10.1371/journal.pone.0180495

Sponsorship Program by CAST [CACM-2017-QNRC2-C15], and Special Scientific Research for Traditional Chinese Medicine [no. 201307006].

ACKNOWLEDGMENTS

We are grateful to Professor Liu Jiaxiang’s guidance in our Chinese medicine prescriptions. SCRC experts were invited to manage the statistical analysis.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2019.00732/full#supplementary-material
non-small-cell lung cancer harboring EGFR mutations. *PLoS One* 9 (2), e85245. doi: 10.1371/journal.pone.0085245

Melosky, B., and Hirsh, V. (2014). Management of common toxicities in metastatic NSCLC related to anti-lung cancer therapies with EGFR-TKIs. *Front. Oncol.* 4, 238. doi: 10.3389/fonc.2014.00238

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurtani, J., et al. (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol.* 11 (2), 121–128. doi: 10.1016/S1470-2045(09)70364-X

Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., et al. (2017). Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. *N. Engl. J. Med.* 376 (7), 629–640. doi: 10.1056/NEJMoa1612674

Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N. Engl. J. Med.* 361 (10), 947–957. doi: 10.1056/NEJMoa0810699

Ramalingam, S. S., Yang, J. C., Lee, C. K., Kurata, T., Kim, D. W., John, T., et al. (2018). Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. *J. Clin. Oncol.* 36 (9), 841–849. doi: 10.1200/JCO.2017.74.7576

Riely, G. J., Pao, W., Pham, D., Li, A. R., Rizvi, N., Venkatraman, E. S., et al. (2006). Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. *Clin. Cancer Res.* 12 (3 Pt 1), 839–844. doi: 10.1158/1078-0432.CCR-05-1846

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., et al. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 13 (3), 239–246. doi: 10.1016/S1470-2045(11)70393-X

Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., et al. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. *N. Engl. J. Med.* 361 (10), 958–967. doi: 10.1056/NEJMoa0904554

Shi, Y., Zhang, L., Liu, X., Zhou, C., Zhang, L., Zhang, S., et al. (2013). Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (JCOGEN): a randomised, double-blind phase 3 non-inferiority trial. *Lancet Oncol.* 14 (10), 953–961. doi: 10.1016/S1470-2045(13)70355-3

Shi, Y. K., Wang, L., Han, B. H., Li, W., Wu, Y., Liu, Y. P., et al. (2017). First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. *Ann. Oncol.* 28 (10), 2445–2450. doi: 10.1093/annonc/mdx359

Thongprasert, S., Duffield, E., Saigo, N., Wu, Y. L., Yang, J. C., Chu, D. T., et al. (2011). Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). *J. Thorac. Oncol.* 6 (11), 1872–1880. doi: 10.1097/JTO.0b013e31822adaf7

Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., et al. (2015). Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small-cell lung cancer harboring EGFR T790M. *Nat. Med.* 21 (6), 560–562. doi: 10.1038/nm.3854

Wang, Q., Jiao, L., Wang, S., Chen, P., Bi, L., Zhou, D., et al. (2018). Maintenance chemotherapy with chinese herb medicine formulas vs. with placebo in patients with advanced non-small cell lung cancer after first-line chemotherapy: a multicenter, randomized, double-blind trial. *Front. Pharmacol.* 9, 1233. doi: 10.3389/fphar.2018.01233

Wei, S. (2018). Yin-yang regulating effects of cancer-associated genes, proteins, and cells: an ancient chinese concept in vogue in modern cancer research. *Biosci. Trends.* 11 (6), 612–618. doi: 10.5582/bst.2017.01259

Xu, L., Meng, X., Xu, N., Fu, W., Tan, H., Zhang, L., et al. (2018). Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth. *Cell Death Dis.* 9 (3), 262. doi: 10.1038/s41419-018-0314-6

Yang, X. B., Wu, W. Y., Long, S. Q., Deng, H., and Pan, Z. Q. (2014). Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study. *Complement. Ther. Med.* 22 (6), 1010–1018. doi: 10.1016/j.ctim.2014.10.001

Yang, X. B., Chai, X. S., Wu, W. Y., Long, S. Q., Deng, H., Pan, Z. Q., et al. (2017). Gefitinib plus Fuwuzh Kang’ai Formula (扶正抗癌方) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: a randomized controlled trial. *Chin. J. Integ. Med.* 24 (10), 734–740. doi: 10.1007/s11655-017-2819-8

Yu, P. P., Vose, J. M., and Hayes, D. F. (2015). Genetic cancer susceptibility testing: increased technology, increased complexity. *J. Clin. Oncol.* 33 (31), 3533–3534. doi: 10.1200/JCO.2015.63.3628

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., et al. (2013). Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. *Clin. Cancer Res.* 19 (8), 2240–2247. doi: 10.1158/1078-0432.CCR-12-2246

Zhang, Y., Sheng, J., Kang, S., Fang, W., Yan, Y., Hu, Z., et al. (2014). Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. *PLoS One* 9 (9), e107161. doi: 10.1371/journal.pone.0107161

Zhou, C., Wu, Y. L., Chen, G., Feng, J., Liu, X., Qiao, C., et al. (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol.* 12 (8), 735–742. doi: 10.1016/S1470-2045(11)70184-X

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.